ESC Congress 2017: Meet us at Booth M500 in the Exhibition Area
At this year's ESC Congress (European Society of Cardiology) in Barcelona, visitors can learn all about our contribution to the treatment of cardiovascular diseases. At our booth M500 in the exhibition area, we will have a number of presentations and sessions coming up. Leading cardiology experts will talk about atrial fibrillation (AF), venous thromboembolism (VTE) as well as cancer associated VTE to raise awareness around Daiichi Sankyo as a key player in the industry that is deeply committed in the cardiovascular and anticoagulation area. There will be satellite symposia, interactive cases and discussions, webinars and lots of other activities. At the congress, we want to make clear that our defined aim as a company is to improve the treatment and thereby the quality of life for patients with cardiovascular diseases. We look forward to presenting and discussing information on new ways to care for patients with everyone visiting our booth!
About the ESC Congress
Every year, the ESC Congress attracts over 30,000 clinicians, scientists, epidemiologists, nurses, technicians, key opinion leaders and policy makers from around the globe as it the most important plattform to learn about the most recent developments and innovations in the diagnosis, treatment and prevention of cardiovascular disease. In 2017, the spotlight is "40 years of PCI" to highlight the impact that Percutaneous Coronary Interventions have had on all aspects of cardiovascular care. Over 500 sessions and a distinguished faculty including the most respected international scientists and clinicians will provide an unmatched scientific and educational programme covering the entire scope of cardiovascular science.
We are looking forward to meeting you at our booth! Follow us on Twitter (@EUdaiichisankyo) for updates during the congress!
The world's largest and most influential cardiovascular event
We look forward to welcoming you at the ESC Congress 2017 to discuss steps which can improve the treatment and thereby the quality of life for patients with heart diseases.